POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy could help control advanced gastroesophageal cancer that cannot be surgically removed. Sixteen participants received the combination to see if it could shrink or elimin…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:59 UTC
-
New way to deliver chemotherapy shows promise for stomach cancer patients
Disease control OngoingThis early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study includes 27 pa…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC